Asuragen Licenses Xenomics' IP for Leukemia-linked Gene | GenomeWeb
NEW YORK (GenomeWeb News) - Xenomics said today it has granted a co-exclusive license to Asuragen to use the NPM1 gene to develop diagnostic products for acute myeloid leukemia patients.
 
Under the sub-license agreement, Asuragen will have access to use the nucleophosmin gene, or NPM1, toward developing tests to diagnose, stratify, and monitor AML patients.
 
Xenomics holds exclusive rights to a recent discovery at the University of Perugia that has shown that many AML patients have mutations in that gene.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.